Hongyun Biotechnology
Latest round
- Series B
Last raised
- May 2023
Total raised
- $30M
Investors
- 9
About Hongyun Biotechnology
Established in 2018 and based in Nanjing, China, Hongyun Biotechnology is a biopharmaceutical company that develops clinical-stage small molecule drugs. The company focuses on structural pharmacology and integrates cutting-edge computational technologies such as molecular dynamics simulation, computational chemistry and artificial intelligence to develop new drugs. The company has built a number of small molecule innovative drug development pipelines covering targeted therapeutic areas for tumor resistance, rare diseases and other major diseases with high clinical demand., which is an inhibitor for the treatment of multiple non-small cell lung cancers with EGFR activating or drug-resistant mutations. Meanwhile, a first-in-class target program targeting a variety of tumors, including breast cancer, has entered the PCC phase and is expected to be filed in the clinic in 2024.
Who invested in Hongyun Biotechnology
9 investors across 4 rounds
See all investors in Hongyun Biotechnology
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Hongyun Biotechnology
Who invested in Hongyun Biotechnology?
Hongyun Biotechnology has 9 investors on record across 4 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Hongyun Biotechnology raised?
Hongyun Biotechnology has raised 4 venture rounds. Sign up free to see how much each round raised and the total.
When did Hongyun Biotechnology last raise money?
Hongyun Biotechnology's most recent round on record is a Series B, in May 2023.
What does Hongyun Biotechnology do?
Established in 2018 and based in Nanjing, China, Hongyun Biotechnology is a biopharmaceutical company that develops clinical-stage small molecule drugs.
Where is Hongyun Biotechnology headquartered?
Hongyun Biotechnology is headquartered in Nanjing, China.
Which VCs invest in companies like Hongyun Biotechnology?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Yufu Capital, ICBC Capital Management and Ningbo Tongshang Fund back biotechnology companies at Hongyun Biotechnology's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series B
Raising like Hongyun Biotechnology? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.